Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cerebral palsy.

Michael V Johnston1, Alexander H Hoon

  • 1Kennedy Krieger Institute and Department of Neurology, Johns Hopkins University School of Medicine, 707 North Broadway, Baltimore, MD 21205, USA. Johnston@kennedykrieger.org

Neuromolecular Medicine
|October 10, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Informed consent in assisted reproductive technology: Implications for pediatric clinicians.

Developmental medicine and child neurology·2024
Same author

A second dimension of somatosensory system injury? Thalamic volume loss and neuropathic pain in adults with cerebral palsy and periventricular white matter injury.

Annals of the Child Neurology Society·2024
Same author

Assisted reproductive technology: Short- and long-term outcomes.

Developmental medicine and child neurology·2022
Same author

Clinical Factors Associated With Chronic Pain in Communicative Adults With Cerebral Palsy: A Cross-Sectional Study.

Frontiers in pain research (Lausanne, Switzerland)·2022
Same author

Cerebral palsy and the placenta: A review of the maternal-placental-fetal origins of cerebral palsy.

Experimental neurology·2022
Same author

Sustained peripheral immune hyper-reactivity (SPIHR): an enduring biomarker of altered inflammatory responses in adult rats after perinatal brain injury.

Journal of neuroinflammation·2021

Cerebral palsy (CP) stems from fetal or neonatal brain disturbances. Key mechanisms include periventricular white matter injury and excitotoxicity, with mild hypothermia showing promise for treatment.

Area of Science:

  • Neuroscience
  • Developmental Pediatrics
  • Pathology

Background:

  • Cerebral palsy (CP) involves movement and posture disorders from nonprogressive fetal/neonatal brain disturbances.
  • Periventricular white matter injury (PWMI) is the most common lesion, particularly in preterm infants, affecting oligodendrocytes.
  • Prenatal factors cause most CP in term infants, while both prenatal and postnatal causes contribute to CP in premature infants.

Purpose of the Study:

  • To elucidate the molecular mechanisms underlying brain injury in cerebral palsy.
  • To differentiate injury patterns and mechanisms in term versus preterm infants.
  • To review potential therapeutic strategies for neonatal brain injury and CP.

Main Methods:

  • Review of pathological lesions in cerebral palsy, focusing on periventricular white matter injury (PWMI).

Related Experiment Videos

  • Analysis of molecular mechanisms including oxidative stress and excitotoxicity.
  • Examination of injury patterns related to asphyxia and hypoxic-ischemic encephalopathy in term infants.
  • Discussion of experimental models of neonatal brain injury and apoptosis.

    • Main Results:

    • PWMI, linked to immature oligodendrocytes, causes spastic diplegia and cognitive deficits.
    • Excitotoxicity via glutamate receptors is a primary mechanism for PWMI.
    • Asphyxia in term infants leads to a distinct injury pattern affecting cortex, basal ganglia, and brainstem.
    • Neonatal neurons undergo delayed apoptosis, involving caspase-dependent and -independent pathways.

    Conclusions:

    • Understanding molecular pathways like excitotoxicity is crucial for CP research.
    • Mild hypothermia is a promising treatment for asphyxia-related neonatal brain injury.
    • Future strategies may combine hypothermia with pharmacological interventions for CP.